News Stanford and twoXAR strike deal to take on liver cancer Stanford University School of Medicine is to take on liver cancer by teaming with twoXAR to develop new drug candidates.
News Reaction to MSD's UK exit as government tries to renew talks The UK government is reported to be trying to restart talks over drug pricing and rebates after MSD's shock decision to scrap a £1bn investment spend.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
